|
Not yet recruiting
|
NCT06411301 -
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
|
Phase 1 |
|
Recruiting
|
NCT05008536 -
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
|
Early Phase 1 |
|
Recruiting
|
NCT06158412 -
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
|
Phase 2 |
|
Recruiting
|
NCT05121103 -
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
|
Phase 1 |
|
Recruiting
|
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 |
|
Recruiting
|
NCT04657861 -
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
|
Early Phase 1 |
|
Terminated
|
NCT05191472 -
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
|
Phase 2 |
|
Active, not recruiting
|
NCT04688853 -
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
|
Phase 1 |
|
Not yet recruiting
|
NCT05050305 -
Marizomib Central Nervous System (CNS)
|
Phase 2 |
|
Recruiting
|
NCT05546723 -
LMY-920 for Treatment of Relapsed or Refractory Myeloma
|
Phase 1 |
|
Not yet recruiting
|
NCT06115135 -
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
|
Phase 2 |
|
Not yet recruiting
|
NCT06225310 -
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
|
Phase 1 |
|
Recruiting
|
NCT05673083 -
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
|
|
|
Completed
|
NCT02176213 -
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
Phase 2 |
|
Enrolling by invitation
|
NCT04861480 -
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
|
Phase 1 |
|
Not yet recruiting
|
NCT05909826 -
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
|
Phase 2 |
|
Recruiting
|
NCT04414475 -
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
|
Phase 2 |
|
Completed
|
NCT04811898 -
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
|
Phase 1 |
|
Recruiting
|
NCT05739188 -
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT05747586 -
BCMA CAR-NK For Patients With RRMM
|
N/A |